NCT03915275Unknown不适用
Clinical Impact of 16S rDNA PCR, a Monocentric Retrospective Study
University Hospital, Strasbourg, France1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Study of the modification of the care of the patients by the use of the 16S PCR
研究概览
简要总结
The main objective of this study is to evaluate the impact of a positive 16S rDNA PCR in various sites on patient's management.
The secondary objectives of the protocol are:
- to evaluate bacterial identification performance
- to evaluate the effect of previous antibiotic therapy
- to analyze the management of discordant results between 16S PCR and culture identification
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients that had a 16S rDNA PCR positive result in Strasbourg University Hospital laboratory from 2014 to 2018
- •Patients consent for this analysis of their past medical history
- •Legal guardians consent for the analysis of their children's medical history
排除标准
- •Patients who express opposition for this study
- •Incomplete clinical record
结局指标
主要结局
Study of the modification of the care of the patients by the use of the 16S PCR
时间窗: The period from Junuary 1st, 2014 to Dcember 31, 2018 will be examined
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A study to assess if molecular analysis of certain leprosy specific genes shall be helpful in monitoring response to therapy in leprosyCTRI/2017/11/010609IADVL Research Grants
已完成
2 期
Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 DiabetesPreDiabetesNCT05990205Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran437
已完成
2 期
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's DiseaseHuntington DiseaseNCT00724048Teva Branded Pharmaceutical Products R&D, Inc.227
已完成
3 期
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's DiseaseHuntington's DiseaseNCT00665223Teva Branded Pharmaceutical Products R&D, Inc.437
进行中（未招募）
不适用
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant TreatmentNon Small Cell Lung Cancer Stage IIINeoadjuvant TreatmentNCT05382052Fundación GECP100